Organon faces profitability challenges and revenue declines. The valuation appears fair given the weak revenue outlook. See ...

Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same ...

NEW YORK, June 14, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Organon & Co. (NYSE: OGN) and certain of the ...

Global pharmaceutical manufacturing ... biosimilars, and over 60 products and therapies for women's health. Organon & Co. (NYSE:OGN) has a strong range of products and is always trying to make ...

NEW YORK, June 08, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Organon & Co. (NYSE: OGN) and certain of the ...

Daré Bioscience stockholders as of close of business on the April 17, 2025 record date for the Annual Meeting, or their legal ...

In addition to Organon’s current products, the company invests in ... and indirect impacts of tariffs (including any potential pharmaceutical sector tariffs), trade sanctions or similar ...

In addition to Organon’s current products, the company invests in innovative solutions ... including the direct and indirect impacts of tariffs (including any potential pharmaceutical sector tariffs), ...

Daré Bioscience, Inc. (NASDAQ: DARE), a biopharmaceutical company driven by a mission to challenge the status quo, making women's health a priority, and Rosy Wellness, a pioneering digital platform ...

Organon & Co. top brass misrepresented its financial condition and strategy before the company said it slashed quarterly dividends about 70%, prompting a record stock selloff, a shareholder lawsuit ...